U.S. Communications Stock News

This article examines whether Compass, trading at around US$7.89, represents a bargain or is already pricing in its current story, and explores what that price might imply about value. The stock has delivered mixed returns, with a 0.8% move over the last week, 11.4% over the last month, a 24.9% decline year to date, and a 3.4% return over the past year, which can shape how investors think about both potential upside and risk. Recent coverage has focused on Compass as a real estate brokerage...

If you are wondering whether Roper Technologies at around US$354 per share still offers value, it helps to start by separating the recent share price moves from what the business might be worth. The stock has seen mixed returns, with a 2.9% decline over the last 7 days, a 0.6% gain over 30 days, and longer term returns of an 18.5% decline year to date and a 36.3% decline over the past year. Recent headlines around Roper Technologies have focused on its position in the software space and how...

In recent days, Chevron has been reported in advanced talks to sell a portfolio of Asian assets to Eneos in a deal potentially valued at more than US$2.00 billion, while also signing a memorandum of understanding with Libya’s National Oil Corporation to evaluate unconventional shale oil and gas resources. These moves suggest Chevron is actively reshaping its portfolio and geographic exposure, potentially freeing capital from mature Asian operations to assess higher‑potential unconventional...

If you are wondering whether ServiceNow is priced fairly or offering value right now, the starting point is to look closely at what the current share price actually reflects about the business. The stock closed at US$90.49 recently, with returns of 9.6% decline over 7 days, 9.0% decline over 30 days, 38.6% decline year to date and 52.0% decline over the last year. This puts recent performance front and center for any valuation discussion. Recent coverage has focused on how this share price...

Nucor (NUE) opened Q1 2026 with revenue of about US$9.5b and basic EPS of US$3.25, setting a clear marker for how the year is starting. The company has seen quarterly revenue move from US$7.1b in Q4 2024 to US$7.8b in Q1 2025 and then to US$9.5b in Q1 2026. Basic EPS shifted from US$1.22 to US$0.67 over the Q4 2024 to Q1 2025 period before landing at US$3.25 in the latest quarter, giving investors plenty to weigh up on how margins are shaping the story. See our full analysis for Nucor. With...

In the first quarter of 2026, QCR Holdings, Inc. reported net interest income of US$67.44 million and net income of US$33.38 million, alongside US$3.9 million in net charge-offs and the repurchase of 247,000 shares for US$20.8 million under its ongoing buyback program. The combination of higher earnings per share and continued share repurchases suggests management is emphasizing both earnings growth and capital returns to shareholders. Next, we’ll examine how this stronger quarterly...

Why Turning Point Brands is on investors’ radar today Turning Point Brands (TPB) has caught investor attention after recent share price swings, with the stock showing gains over the past week but declines over the month and past 3 months. See our latest analysis for Turning Point Brands. At a share price of $77.42, Turning Point Brands has seen a 9.68% 7 day share price return but a 37.81% 90 day share price decline. The 3 year total shareholder return of about 2.4x points to strong longer...

Rambus (RMBS) has opened 2026 with Q1 revenue of US$180.2 million and basic EPS of US$0.55, setting the tone for how its growth story is feeding through to the bottom line. The company has seen quarterly revenue move from US$166.7 million in Q1 2025 to US$180.2 million in Q1 2026, while trailing twelve month EPS sits at US$2.13. This gives investors a clear read on both near term and rolling earnings power as they weigh the implications of slightly lower margins against the growth runway. See...

Abbott Laboratories (NYSE:ABT) received U.S. FDA clearance and CE Mark for its AI powered Ultreon 3.0 Software. Ultreon 3.0 is a next generation coronary imaging platform designed to give physicians real time, AI guided insights during minimally invasive heart procedures. For investors watching Abbott Laboratories at a share price of $93.86, Ultreon 3.0 adds a fresh product development to consider alongside recent share performance. The stock has seen a 1.2% gain over the past week, while...

If you are wondering whether TAL Education Group at around US$10.77 is priced attractively or not, the key question is whether the current share price lines up with the underlying value of the business. The stock has seen mixed returns, with a 9.9% decline over the last 7 days, a 0.5% decline over 30 days, a 6.3% decline year to date, an 18.6% gain over the past year and a 104.8% gain over three years, set against an 80.8% loss over five years. Recent share price moves sit against a backdrop...

If you are wondering whether Avista at around US$41.21 is a fair price, a bargain, or something to be cautious about, this article is designed to help you frame that question clearly before you act. Over the recent period, Avista's share price closed at US$41.21, with returns of 2.1% over 7 days, 3.2% over 30 days, 6.4% year to date, 4.2% over 1 year, 9.8% over 3 years, and 13.1% over 5 years. Recent coverage of Avista has focused on its role in the Integrated Utilities space and how...

ACM Research shipped the world's first three-station rotating PECVD SiCN system, introducing a new architecture for advanced semiconductor manufacturing. The system is designed to improve film stability and process control for advanced back-end-of-line and packaging applications. This shipment marks a fresh addition to ACM Research's product lineup that has not been covered in recent company news. ACM Research (NasdaqGM:ACMR) is drawing attention with this new PECVD SiCN tool at a time when...

If you are wondering whether PTC Therapeutics at around US$70.26 is offering fair value or hidden upside, the starting point is to understand what the current market price is actually baking in. The stock has been volatile, with a 0.5% decline over the last 7 days, a 6.2% gain over the last 30 days, an 8.4% decline year to date, and a 41.9% return over the past year that sits alongside multi year returns of 27.8% over 3 years and 82.6% over 5 years. Behind these moves, investors have been...

Wondering whether PDD Holdings at US$97.29 is offering value right now, or if the market is already pricing in its story? This article walks through what the numbers actually suggest. The stock has seen a 2.8% decline over the last 7 days and a 1.1% decline over the last 30 days, contributing to a 15.9% decline year to date and a 7.8% decline over the last year, while still showing a 53.2% return over three years. These moves are taking place against a backdrop of ongoing interest in large...

United Parcel Service (UPS) opened 2026 with Q1 revenue of US$21.2b and basic EPS of US$1.02, setting the tone for how investors read the rest of the year’s earnings profile. The company has seen quarterly revenue move from US$25.3b in Q4 2024 to US$21.5b in Q1 2025 and US$21.2b in Q1 2026, while basic EPS over those same periods has gone from US$2.02 to US$1.40 and then to US$1.02. This puts more focus on how efficiently UPS converts its top line into profit as margins come under closer...

It's been a good week for Sierra Bancorp ( NASDAQ:BSRR ) shareholders, because the company has just released its latest...

If you are wondering whether ATI is priced for perfection or still offers value at current levels, this breakdown walks through what the recent share moves might be telling you. ATI closed at US$151.70, with a 4.6% decline over the last 7 days, an 8.0% gain over 30 days, a 27.3% gain year to date, and a 182.1% gain over the past year. These moves can change how investors think about both upside and risk. Recent coverage has highlighted ATI in the context of aerospace and defense supply...

If you are wondering whether Tesla's share price still reflects the story you have in mind, this article focuses on what the current market price might imply about the company's value. Tesla recently closed at US$376.02, with returns of 3.9% over 30 days, a 28.8% gain over 1 year, 134.6% over 3 years, and 67.5% over 5 years. Year to date the stock is down 14.2%, and over the last 7 days it has declined 2.7%. Recent headlines have continued to focus on Tesla's role as a major electric vehicle...

Simpson Manufacturing (SSD) has opened 2026 with Q1 revenue of US$588 million and basic EPS of US$2.14, setting the tone after a year in which trailing twelve month revenue reached US$2.4 billion and EPS came in at US$8.55. Over recent quarters the company has seen revenue range from US$539 million to US$631 million and EPS between US$1.32 and US$2.59. This gives investors a clear view of how the top and bottom line have been tracking into this latest print, with margins now a central focus...

If you are wondering whether SPS Commerce's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers say about value. The stock last closed at US$55.29, with returns of 1.5% over 30 days but a 61.1% decline over the past year, which has many investors reassessing both potential upside and risk. Recent coverage has focused on SPS Commerce as a software name facing a very different market mood compared to a few years ago. There is...

Before deciding whether Hubbell fits your portfolio, it helps to ask a simple question: what are you really paying for at today’s price of US$544.71 per share? Recent performance has caught attention, with the stock showing a 13.3% return over 30 days, 17.6% year to date, 53.4% over 1 year and 202.0% over 5 years, alongside a 0.8% decline over the last 7 days that may have some investors reassessing near term risks. Recent news coverage has focused on Hubbell as part of wider discussions...

In April 2026, Compass Therapeutics reported that its Phase 2/3 COMPANION-002 trial in advanced biliary tract cancer met the primary endpoint of overall response rate and a key secondary endpoint of progression-free survival for tovecimig plus paclitaxel versus paclitaxel alone, with no new safety concerns observed. An intriguing finding was that patients who crossed over from paclitaxel alone to the tovecimig combination lived longer than those who stayed on paclitaxel, despite initially...

TriNet Group (NYSE:TNET) has filed an omnibus or universal shelf registration statement. The filing allows the company to issue common and preferred stock, debt securities, warrants, depositary shares, purchase contracts, and units. The shelf registration can be used over time for fundraising, capital structure changes, or acquisition related financing. TriNet Group (NYSE:TNET) provides human resources solutions for small and medium sized businesses, so access to flexible funding tools can...

Xylem (XYL) opened Q1 2026 with revenue of US$2.1 billion and basic EPS of US$0.79, alongside trailing twelve month revenue of US$9.1 billion and basic EPS of US$4.03 that reflect how the business has been performing through the full cycle. Over the past year, revenue has moved from US$8.6 billion to US$9.1 billion on a trailing basis, while basic EPS has shifted from US$3.67 to US$4.03. This gives you a clear read on how the top and bottom line have tracked into this quarter. With a net...